icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
2E0JTuwxMABQwk23